Feasibility and toxicity of interferon maintenance therapy after allogeneic BMT for multiple myeloma: A pilot study of the EBMT

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 759-762

  Samson, D ^a   Volin, L ^b   Schanz, U ^c   Bosi, A ^d   Gahrton, G ^e  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allo BMT; Interferon; Maintenance; Myeloma

Indexed keywords

INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAINTENANCE THERAPY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 0030004393     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Gahrton G, Tura S, Ljungman P et al. Allogeneic BMT using HLA matched sibling donors in multiple myeloma. New Engl J Med 1991; 325: 1267-1273.
2. Attal M, Huguet F. Schlaifer D et al. Maintenance treatment with recombinant alpha-interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional chemotherapy. Bone Marrow Transplant 1991; 8: 125-128.
3. Cunningham D, Viner C. Montes A et al. A randomised trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma. ASCO Proc 1993; 12: 364 (abstr. 1232).
4. Bjorkstrand B, Goldstone AH, Ljungman P et al. Prognostic factors in autologous stem cell transplantation for myeloma: an EBMT registry study. Leuk Lymphoma 1994; 15: 265-272.
5. Gressler VH, Weinkauff RE, Franklin WA, Golomb HM. Modulation of the expression of major histocompatibility antigens on splenic hairy cells - differential effect upon in vitro treatment with alpha-2b-interferon, gamma-interferon and interleukin-2. Blood 1988; 72: 1048-1053.
6. Friedman RM. Vogel SN. Interferons with special emphasis on the immune system. Adv Immunol 1983; 34: 97-140.
7. Klingemann H-G, Phillips GL. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1994; 8: 73-81.
8. Pavord S, Sivakumaran M, Durrant S, Chapman C. The role of alpha-interferon in the pathogenesis of GVHD. Bone Marrow Transplant 1992; 10: 477 (letter).
9. Ratanatharathom V, Uberti J, Karanes C et al. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft-versus-host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 625-630.
10. Higano CS, Raskind WH, Singer JW. Use of alpha interferon for the treatment of relapse of chronic myelogenous leukaemia in chronic phase after allogeneic bone marrow transplantation. Blood 1992; 80: 1437-1442.
11. Arcese W, Goldman JM, D'Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Blood 1993; 82: 3211-3219.